Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
– STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck – – Trial will ...
Read more